Asthma is a chronic inflammatory respiratory disease characterized by coughing episodes, difficult breathing, and wheezing. Various cells participate in the inflammatory process, including mastocytes, eosinophils and T lymphocytes, and asthma is an ideal example of gene-environment interaction. Diagnosis of the disease is carried out following pre-existing guidelines which describe recognizable patterns of respiratory symptoms. According to the function, drugs for the treatment of asthma are divided into control drugs, relievers and additional therapy for patients with severe asthma, and according to the mechanism of action on ICS, β2-agonists, leukotriene receptor antagonists, anticholinergics and macrolide antibiotics. This paper has analysed reports of suspected adverse drug reactions of antiasthmatics from 1.1.1993. to 15.3.2020., obtained from HALMED. According to the ATC classification, antiasthmatics belong to a group R – Respiratory system, i.e. in subgroup R03. A total of 1035 reports were analysed by age and gender of patients, by active substance, system organ class (SOC), most commonly reported adverse drug reactions (PT), seriousness and years. The highest number of adverse drug reaction reports was received for patients aged between 45 and 64 years (23.9%) and for female patients (50.8%). The highest number of adverse drug reaction reports was received for salbutamol (11.8%), montelukast (11.7%) and dexamethasone (10.6%), and the highest number of adverse drug reactions was reported for system organ class General disorders and application site reactions (25.4%). The most commonly reported adverse drug reaction is cough. Most of the adverse drug reaction reports were not assessed as serious, and in the 17 cases the outcome was the patient’s death. Most of the cases are classified as serious according to the criteria “other medically important conditions”. The highest number of adverse drug reaction reports was received in 2019. Continuing education of the healthcare professionals and the patients about the importance of adverse drug reaction reporting and consequently, continuing adverse drug reaction reporting contributes to the evaluation of safety profile of the medicinal products, which ensures that only medicinal products with positive benefit-risk ratio are marketed.